Radioimmunotherapy with I-131-rituximab for patients with relapsed or refractory follicular or mantle cell lymphoma
- Authors
- Jang, Yoon Jung; Lim, Sang Moo; Lee, Inki; Byun, Byung Hyun; Lim, Ilhan; Kim, Byung Il; Choi, Chang Woon; Lee, Seung-Sook; Suh, Cheolwon; Yoon, Dok Hyun; Kim, Inho; Nam, Seung-Hyun; Lee, Mark Hong; Won, Jong Ho; Kong, Jee Hyun; Jeong, Seong Hyun; Oh, Suk Joong; Park, Keon Woo; Han, Jae Joon; Song, Moo-Kon; Yang, Sung Hyun; Na, Im Il; Lee, Hyo-Rak; Shin, Dong-Yeop; Kang, Hye Jin
- Issue Date
- Dec-2023
- Publisher
- Blackwell Pub. Asia
- Keywords
- 131I-rituximab; follicular lymphoma; mantle cell lymphoma; phase II trial; radioimmunotherapy
- Citation
- Asia-Pacific Journal of Clinical Oncology, v.19, no.6, pp 690 - 696
- Pages
- 7
- Journal Title
- Asia-Pacific Journal of Clinical Oncology
- Volume
- 19
- Number
- 6
- Start Page
- 690
- End Page
- 696
- URI
- https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/22566
- DOI
- 10.1111/ajco.13932
- ISSN
- 1743-7555
1743-7563
- Abstract
- AimThis study aimed to evaluate the safety and efficacy of I-131-rituximab in patients with relapsed or refractory follicular or mantle cell lymphoma. MethodsTwenty-four patients with relapsed or refractory follicular or mantle cell lymphoma were administered unlabeled rituximab (70 mg) immediately before receiving a therapeutic dose of I-131-rituximab. Contrast-enhanced 18F-fluorodeoxyglucose positron emission tomography/computed tomography was used a month later to assess tumor response. ResultsThis study enrolled 24 patients between June 2012 and 2022. Depending on how they responded to radioimmunotherapy (RIT), I-131-rituximab was administered one to five times. Of the 24 patients, 9 achieved complete response after RIT and 8 achieved partial response. The median progression-free and overall survival was 5.9 and 37.9 months, respectively. During the follow-up period of 64.2 months, three patients were diagnosed with a secondary malignancy. Among treatment-related adverse events, hematologic toxicities were common, and grade 3-4 thrombocytopenia and neutropenia were reported in 66.6% of cases. Conclusion(131)I-rituximab has an effective and favorable safety profile in patients with relapsed or refractory follicular lymphoma and mantle cell lymphoma. This suggests that RIT may also be considered a treatment option for patients with relapsed or refractory follicular lymphoma and mantle cell lymphoma.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > Department of Internal Medicine > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.